Letter to the Editor

Bioluminescence Imaging of Prenylation Inhibition—Response

Kendall J. Blumer¹, Katherine Weilbaecher², and David Piwnica-Worms³,⁴,⁵

We are grateful to Dr. Clezardin for raising an intriguing point based on his recent article (1). Distinguishing whether ZOL inhibits prenylation in tumor cells and/or host tissues and leads to accumulation of IPP/ApppI or causes other effects leading directly or indirectly to tumor cell killing or elimination has been a persistent challenge to the field. We concur that using our bioluminescence reporter to compare targeting of estrogen receptor (ER)—positive and ER-negative breast cancer cells by ZOL in xenograft models would be a useful approach. Because tumor cells bearing the reporter would be the only source of a bioluminescence signal, such experiments should be capable of determining unambiguously whether ER-positive and ER-negative breast cancer cells differ substantially in the ability to be targeted directly by ZOL in living animals.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Received August 20, 2012; accepted August 20, 2012; published OnlineFirst October 8, 2012.

Reference

Bioluminescence Imaging of Prenylation Inhibition–Response

Kendall J. Blumer, Katherine Weilbaecher and David Piwnica-Worms


Access the most recent version of this article at: doi:10.1158/1078-0432.CCR-12-2737

This article cites 1 articles, 1 of which you can access for free at: http://clincancerres.aacrjournals.org/content/18/21/6078.full#ref-list-1

Sign up to receive free email-alerts related to this article or journal.

To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

To request permission to re-use all or part of this article, use this link http://clincancerres.aacrjournals.org/content/18/21/6078. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.